| Literature DB >> 21333352 |
Eva Gimeno1, Miquel Gómez, Juan Ramón González, Josep Comín, Alberto Alvarez-Larrán, Blanca Sánchez-González, Lluis Molina, Eva Domingo-Domenech, Francesc Garcia-Pallarols, Carmen Pedro, Eugenia Abella, Carles Vilaplana, Silvia de Sanjosé, Carlos Besses, Antonio Salar.
Abstract
NT-proBNP provides diagnostic and prognostic information in heart syndromes but its role in cancer has not yet been established. The prognostic value of NT-proBNP was prospectively studied in 104 non-Hodgkin lymphoma (NHL) patients treated with chemotherapy. Echocardiography and NT-proBNP were determined prior to treatment. In multivariate analysis, NT-proBNP ≥ 900 pg/ml was the variable with higher risk of death (adjusted hazard ratio 11.1; 95% CI 3.8-32.9; P<0.001). The C statistic for NT-proBNP ≥ 900 pg/ml was significantly better than IPI score for prediction of survival. These findings suggest that NT-proBNP ≥ 900 pg/ml could be considered a useful marker for risk assessment in NHL patients treated with chemotherapy.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21333352 DOI： 10.1016/j.leukres.2011.01.018
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156